Avanafil-13C,d3

Avanafil-13C,d3

• CAS Number: 2738376-89-9
• UNSPSC Description: Avanafil-13C,d3 is the 13C- and deuterium labeled Avanafil.
• Target Antigen: Isotope-Labeled Compounds; Phosphodiesterase (PDE)
• Type: Isotope-Labeled Compounds
• Related Pathways: Metabolic Enzyme/Protease;Others
• Applications: Neuroscience-Neuromodulation
• Field of Research: Cardiovascular Disease
• Solubility: 10 mM in DMSO
• Smiles: ClC1=C(O[13C]([2H])([2H])[2H])C=CC(CNC2=C(C(NCC3=NC=CC=N3)=O)C=NC(N4[C@H](CO)CCC4)=N2)=C1
• Molecular Weight: 487.96
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Kotera J, et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188(2):668-74.|[3]Mochida H, et al. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs. J Urol. 2013 Aug;190(2):799-806.|[4]Wang R, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012 Aug;9(8):2122-9.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported